Mydecine Innovations Brings Onboard Ethica CRO As A Research Contract Partner For Phase 2A PTSD Clinical Trials

Mydecine Innovations Group Inc (OTCMKTS:MYCO) looks forward to starting its Phase 2A PTSD clinical trials and sees ethica CRO (“ethica CRO”) as an ideal partner. After considering its excellent work towards introducing a new ethical dimension to clinical research, the business giant has chosen the partner.

CRO’s accreditations

The other thing that makes the partner ideal is that it became the first CRO to receive accreditation as a significant player in a human research protection program conducted back in 2006. Some people would also see the CRO getting accreditation from about three accrediting bodies as a significant achievement and qualification for the new partnership.

The CEO of Mydecine Innovations Group, Josh Bartch, applauded the move to collaborate with such a top-class partner. He hopes that the CRO’s outstanding expertise in managing clinical studies will be a great addition to their success in the upcoming Phase 2A PTSD clinical trials.

The official sees the move to bring onboard the new partner to show their outstanding preparations towards discovering how the brain reacts to psychedelics. The parties will also be looking to establish what a psychedelic experience could cause in biological underpinnings.

Mydecine wants to push its clinical development to the pinnacle, and it will be counting on its partner’s unparalleled experience in wide-ranging trials. Ethica CRO is known for its deep clinical expertise and will help a lot with the trial preparations.

Jensen’s perspective

The Managing Director of ethica CRO Murray Jensen is happy about the impressive mental health treatment changes. He terms Psychedelics and psychedelic-assisted therapies as some of the game-changers as they continue to progress with their innovation drive.

Mydecine is pleased to announce its partnership with Microdose Psychedelic Insights, a move that will see the two focus on unveiling a free, live webinar series. Reports show that the series will entirely focus on the Renaissance of Psychedelics.